Se-Methylselenocysteine (hydrochloride) (Synonyms: Methylselenocysteine, Se-MeSeCys, Se-methyl-L-Selenocysteine) |
| Catalog No.GC48914 |
Se-Methylselenocysteine (hydrochloride) (MSC)은 세렌시스틴 메틸화의 유도체로 자연적인 단일메틸화된 셀레노 아미노산이다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 863394-07-4
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Se-Methylselenocysteine (hydrochloride) (MSC)은 세렌시스틴 메틸화의 유도체로 자연적인 단일메틸화된 셀레노 아미노산이다. Se-Methylselenocysteine은 주로 항노화, 셀레늄 보충, 심혈관/뇌혈관질환 치료 및 항산화에 사용된다[1]. Se-Methylselenocysteine은 구강 내 복용이 가능하고 세포의 조기사기를 유발한다[2,3].
Se-Methylselenocysteine (100-400 µM; 3일)은 SKOV-3 유방암 세포에서 칼파인에 의해 중계되는 캡사스 활성화와 Bax 분해를 통해 조기사기를 유도한다[4]. Se-Methylselenocysteine (200 µM; 24시간)은 EA(elaidic acid)에 의해 인한 세포 생존력 저하를 효과적으로 되돌릴 수 있다[5]. 최적 농도인 1 µM의 Se-Methylselenocysteine은 클러스터린(Clu)-nockdown에 의해 야기된 항산화 능력, Bcl2/Bax 비율 및 캡사스-8 활성화의 변화를 되돌려 조기사기를 억제하고 세포 생존력을 유지할 수 있다[6].
Se-Methylselenocysteine (0.2 mg/쥐; 구강 투여; 연속 14일)은 인간 FaDu 및 A253 머리 및 목 부위 이식물을 가진 나체 쥐에서 Cisplatin (cis-diamminedichloroplatinum (CDDP))과 Cyclophosphamide의 항종 활성을 증진시킨다[7]. Se-Methylselenocysteine (0.3 /1/3 mg/kg; 10주; 구강 투여) 치료는 간 손상을 완화시켰다. Se-Methylselenocysteine 농도가 증가함에 따라 쥐의 간 조직 손상도는 점차적으로 감소했다[8].
References:
[1]. Johnson WD, Morrissey RL, et,al. Subchronic toxicity studies of Se-methylselenocysteine, an organoselenium compound for breast cancer prevention: Food Chem Toxicol, 2008; 46; 1068-78
[2]. El-Bayoumy K, Sinha R, Mechanisms of mammary cancer chemoprevention by organoselenium compounds: Mutat Res, 2004; 551; 181-97
[3]. Medina D, Thompson H, et,al.Se-methylselenocysteine: A new compound for chemoprevention of breast cancer: Nutr Cancer, 2001; 40; 12-17
[4]. Yeo JK, Cha SD, et,al. Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. Cancer Lett. 2002 Aug 8;182(1):83-92. doi: 10.1016/s0304-3835(02)00075-7. PMID: 12175527.
[5]. Xia J, Xia X, et,al. Protective Effect of Se-Methylselenocysteine on Elaidic Acid-Induced Inflammation in Human Arterial Endothelial Cells. J Nutr Sci Vitaminol (Tokyo). 2020;66(6):577-582. doi: 10.3177/jnsv.66.577. PMID: 33390400.
[6]. Wang C, Zeng Z, et,al. Se-methylselenocysteine inhibits apoptosis induced by clusterin knockdown in neuroblastoma N2a and SH-SY5Y cell lines. Int J Mol Sci. 2014 Nov 18;15(11):21331-47. doi: 10.3390/ijms151121331. PMID: 25411798; PMCID: PMC4264228.
[7]. Cao S, Durrani FA, et,al. Se-methylselenocysteine offers selective protection against toxicity and potentiates the antitumour activity of anticancer drugs in preclinical animal models. Br J Cancer. 2014 Apr 2;110(7):1733-43. doi: 10.1038/bjc.2014.85. Epub 2014 Mar 11. PMID: 24619073; PMCID: PMC3974093.
[8]. Ding J, Qi C, et,al. Se-Methylselenocysteine Alleviates Liver Injury in Diethylnitrosamine (DEN)-Induced Hepatocellular Carcinoma Rat Model by Reducing Liver Enzymes, Inhibiting Angiogenesis, and Suppressing Nitric Oxide (NO)/Nitric Oxide Synthase (NOS) Signaling Pathway. Med Sci Monit. 2021 Aug 4;27:e929255. doi: 10.12659/MSM.929255. PMID: 34344856; PMCID: PMC8351367.
| 세포 실험 [1]: | |
세포 라인 | SKOV-33세포 |
제조 방법 | |
반응 조건 | 100-400 µM; 3 일 |
응용 분야 | Se-Methylselenocysteine(MSC)는 SKOV-33세포에서 세포사멸을 유도합니다. |
| 동물 실험 [2]: | |
동물 모형 | Sprague-Dawley쥐(120 에서 150 g) |
제조 방법 | 쥐는 무작위로 정상 대조군(n=16), 모델군(n=16), Se-Methylselenocysteine (MSC) 처리군(n=48)으로 나뉩니다. 정상 대조군의 쥐는 MSC를 포함하지 않은 정상식을 먹였습니다. 모델군의 쥐는 6주간 연속하여 매주 5회, 0.1 mg/kg MSC를 포함한 정상 식을 먹였습니다. |
제형 | 0.3 /1/3 mg/kg;10주령; p.o. |
응용 분야 | MSC 치료는 간 손상을 완화시켰습니다. MSC 농도가 증가함에 따라 간 조직 손상도는 점차적으로 감소했습니다. |
참고문헌: [1].Yeo JK, Cha SD,et,al. Se-methylselenocysteine induces apoptosis through caspase activation and Bax cleavage mediated by calpain in SKOV-3 ovarian cancer cells. Cancer Lett. 2002 Aug 8;182(1):83-92. doi: 10.1016/s0304-3835(02)00075-7. PMID: 12175527.[2].Ding J, Qi C, et,al. Se-Methylselenocysteine(MSC) Alleviates Liver Injury in Diethylnitrosamine (DEN)-Induced Hepatocellular Carcinoma Rat Model by Reducing Liver Enzymes, Inhibiting Angiogenesis, and Suppressing Nitric Oxide (NO)/Nitric Oxide Synthase (NOS) Signaling Pathway. Med Sci Monit. 2021 Aug 4;27:e929255. doi: 10.12659/MSM.929255. PMID: 34344856; PMCID: PMC8351367. | |
| Cas No. | 863394-07-4 | SDF | |
| Synonyms | Methylselenocysteine, Se-MeSeCys, Se-methyl-L-Selenocysteine | ||
| Canonical SMILES | C[Se]C[C@H](N)C(O)=O.Cl | ||
| Formula | C4H9NO2Se •HCl | M.Wt | 218.6 |
| Solubility | DMF: 1 mg/ml,DMSO: 1 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 4.5746 mL | 22.8728 mL | 45.7457 mL |
| 5 mM | 0.9149 mL | 4.5746 mL | 9.1491 mL |
| 10 mM | 0.4575 mL | 2.2873 mL | 4.5746 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 33 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *